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NAMPTBerberine (BBR) has recently been shown to improve insulin sensitivity in rodent models of insulin resis-
tance. Although this effect was explained partly through an observed activation of AMP-activated protein ki-
nase (AMPK), the upstream and downstream mediators of this phenotype were not explored. Here, we show
that BBR supplementation reverts mitochondrial dysfunction induced by High Fat Diet (HFD) and hypergly-
cemia in skeletal muscle, in part due to an increase in mitochondrial biogenesis. Furthermore, we observe
that the prevention of mitochondrial dysfunction by BBR, the increase in mitochondrial biogenesis, as well
as BBR-induced AMPK activation, are blocked in cells in which SIRT1 has been knocked-down. Taken togeth-
er, these data reveal an important role for SIRT1 and mitochondrial biogenesis in the preventive effects of BBR
on diet-induced insulin resistance.
© 2011 Elsevier B.V. All rights reserved.1. Introduction
The global emergence of obesity as an epidemic has made it a
worldwide public health problem, promoted by a sedentary lifestyle
and a diet rich in fats and sugar [1,2]. Indeed, obesity has been linked
to numerous health-related pathologies. Visceral obesity is associated
with insulin resistance, dyslipidemia, hypertension and increased risk
of atherosclerosis, a condition known as metabolic syndrome [3].
Metabolic syndrome results from a positive energy balance, in
which caloric intake exceeds oxidation, leading to a disregulation of
glucose and lipid metabolism [4].
Skeletal muscle plays an important role in the development of the
metabolic syndrome [3,5,6]. Since the oxidative capacity of skeletal
muscle is predominately dependent on mitochondria, there is grow-
ing evidence suggesting that mitochondrial dysfunction, and the as-
sociated impairment of fatty acid oxidation, may directly cause or
accelerate insulin resistance [7,8]. This has been shown in patients
with insulin resistance and type 2 diabetes [9–12], as well as in sever-
al animal models [13,14]. In skeletal muscle, stimulation of AMPK and
SIRT1 has been shown to increase the expression and activity of per-
oxisome proliferator activated receptor gamma (PPARγ) coactivatorand Cell Biology, Department
ra, Portugal.
), anpiro@ci.uc.pt (A.P. Rolo).
rights reserved.1-alpha (PGC-1alpha), an essential cofactor involved in mitochondrial
biogenesis [15,16].
The mammalian sirtuins (SIRT1–SIRT7) have been implicated in a
number of cellular and physiological processes including gene silenc-
ing, apoptosis, mitochondrial function, energy homeostasis, and lon-
gevity [17]. SIRT1 has emerged as a key regulator of mammalian
metabolism, and has been shown to deacetylate and activate PGC-
1apha [16,18]. Furthermore, several SIRT1 activators were recently
demonstrated to improve key features of the metabolic syndrome.
The beneﬁcial effects of SIRT1 activation are related with metabolic
changes similar to those triggered by caloric restriction, including im-
provement of mitochondrial function in skeletal muscle [19–21].
Berberine (BBR), [18,5,6-dyhydro-9,10-dimethoxybenzo(g)-1,3ben-
zodioxolo(5.6-a) quinolizinium], is an isoquinoline alkaloid derived
from the Berberidacea plant family, which has been used in traditional
Chinese medicine for centuries. Multiple pharmacologic effects of BBR
have been reported including anti-inﬂammatory [22], anti-hypertensive
[23], and anti-proliferative actions [24]. Moreover, beneﬁcial effects of
BBR on insulin sensitivity and glucose tolerance have shown promise in
the treatment of metabolic disorders such as hyperglycemia and hyper-
lipidemia [25–28]. These effects are related, in part, to the ability of ber-
berine to activate AMPK [25,27,29] and to suppress gluconeogenesis [30].
Since SIRT1 activity is reported to be regulated through AMPK [31]
and SIRT1 can also regulate AMPK activity [32], it is tempting to spec-
ulate that the beneﬁcial effects of BBR on metabolism may be
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mentation increases skeletal muscle mitochondrial biogenesis and
improves mitochondrial function in a rodent model of diet induced
obesity. Furthermore, we show that these effects are SIRT1-
dependent. These effects are associated with signiﬁcant reductions
in adiposity and improvements in overall insulin sensitivity.
2. Materials and methods
2.1. Animals, diets and treatments
Male Sprague Dawley rats aged 6–8 weekswere housed under a 12–
12 h light/dark cycle at 22 °C and given free access to water and stan-
dard chow (Control group) or high fat diet (HFD) for 12 weeks. After
the 12 weeks a third group of rats was maintained on HFD with a sup-
plement of berberine (100 mg/kg/day) in the drinking water for 4
more weeks (HFD+BBR). Berberine intake was monitored over the
course of the study. The diets were purchased from Research Diets, Inc
(New Jersey, USA). The diet used to induce obesity (HFD) has 60% kcal
from fat, whereas the control diet (Ctl) has 10% kcal from fat. All exper-
imental procedures respected the guidelines of the European Directive
86/609/CEE and present in the Portuguese law.
2.2. Surgical procedures, body composition and glucose tolerance test
Chronic indwelling catheters were implanted and the animals
were monitored daily and the catheters ﬂushed with saline. All ani-
mals were allowed to recover for 5 days. Experiments were per-
formed on conscious, unrestrained animals fasted for 24 h. A saline
solution enriched to 70% with 2H2O was administered via the jugular
catheter for 225 min to measure total body water and fat-free mass
(FFM). 2H-enrichments of plasma water and infusate precursor
were quantiﬁed using 2H NMR as describe before [33,34]. For deter-
mining 2H-body water enrichment, a blood sample was taken at
225 min, or 45 min after the infusion was terminated. The body
water pool (ml) for each animal was quantiﬁed from the ratio of infu-
sate to plasma body water 2H-enrichment of the 225 minute sample
multiplied by the total volume of infused 2H2O. Body water mass
(grams) was assumed to be equal to body water volume. FFM was
calculated by dividing the body water mass by 0.73 [33]. Fat mass
was calculated by subtracting FFM from the total body weight. To de-
termine insulin sensitivity and glucose tolerance a glucose tolerance
test was performed, by oral gavage of 1.5 g glucose/kg body weight.
Blood samples were taken from the tail vein at several time points
after the bolus injection and the concentration of glucose for each
sample was measured.
2.3. Glucose, triglycerides and hormone levels
Plasma glucose was determined by a glucometer (Accu-cheK Aviva
— Roche, Portugal) and by a glucose microplate assay kit (Invitrogen,
Spain). Plasma insulin levels were determined by ELISA (EZRMI-13K
—Millipore, Portugal). Plasma leptin and adiponectin levels were mea-
sured using a commercially available kit (Invitrogen, Spain). Triglycer-
ides were extracted using isopropanol and quantiﬁed using a
colorimetric based commercial available kit (Cromatest, Spain).
2.4. C2C12 cell cultures and treatments
C2C12 cell line (ATCC)was cultured in low glucose Dulbecco's mod-
iﬁed eagle medium (DMEM) (Invitrogen) supplemented with 10% FBS
(Invitrogen) and mix of antibiotic and antimycotic (Invitrogen). Differ-
entiation of C2C12 myoblasts to myotubes was achieved by allowing
the cells to reach conﬂuence and then replacing the FBS with 2%
Horse Serum (Invitrogen) for 6 days. C2C12 cells were cultured in
high glucose media (25 mM) for 96 h to mimic hyperglycemicconditions or with 500 μM of Palmitate and Oleate in a ratio of 1:1
(FFAs) [35] to mimic hyperlipidemic conditions. For experiments per-
formed with FFAs, the cells were cultured in medium containing 0.5%
of BSA (Sigma-Aldrich) [35]. Cells treated with 25 mM glucose or FFAs
were also treated with the vehicle (0.001% DMSO) or 5 μMof Berberine
chloride (BBR) for the entire period of treatment. To investigate the in-
tracellular pathways involved in BBR effects on mitochondrial function
and mitochondrial biogenesis, C2C12 myotubes were treated with the
vehicle (0.001% DMSO), 1 μM of EX-527, or 10 μM DCHC during the
same period of treatment with hyperglycemia or fatty acids. To investi-
gate the short term effects of BBR on mitochondrial function, C2C12
cells were cultured in low glucose DMEM with the vehicle (0.001%
DMSO), BBR 5 μM and 20 μM BBR for 6, 12 and 24 h. To further address
the role of NAMPT in BBR mediated effects, C2C12 cells were treated
with 5 μM BBR or 5 μM BBR plus 10 nM FK866 for 12 h.2.5. SIRT1 gene silencing in C2C12 cells
SIRT1 shRNA and control shGFP lentivirus were produced by co-
transfection of 293T cells with plasmids encoding Vsv-g, Δ8.9, pLKO-
shSIRT1 (mouse) or pLKO-shGFP using FuGENE HD in accordance
with the manufacturer's protocol. The Oligo ID for the SIRT1 mouse
hairpin used was TRCN0000039296 (Open Biosystems). Media was
changed 24 h post-transfection. Virus was harvested after 48 h, ﬁltered,
and used to infect C2C12 cells in the presence of 5 μg/mL polybrene via
spin infection (2500 rpm, 30 min). Selection of resistant colonies was
initiated 24 h later using 2 μg/mL puromycin.2.6. Mitochondrial function
Skeletal muscle mitochondria were isolated as described previ-
ously [36] with minor modiﬁcations. Oxygen consumption of isolated
mitochondria was polarographically determined with a Clark oxygen
electrode as described [37]. State 3 respiration was induced with the
addition of 200 nmol of ADP and FCCP-induced respiration was in-
duced by the addition of 1 μM of FCCP. Succinate Dehydrogenase
and Cytochrome c Oxidase activities were polarographically mea-
sured as previously described [38–40]. ATPase activity was deter-
mined spectrophotometrically as described [40]. Mitochondrial
membrane potential in C2C12 cells was measured with a ﬂuorescent
probe, Tetramethylrhodamine methyl ester (TMRM) (Sigma) as de-
scribed before [41] and the ATP content was measured with a com-
mercial kit according to the manufacturer's instructions (Roche).
Endogenous mitochondrial ATP was extracted using an alkaline ex-
traction procedure and was measured using a commercially available
kit according to the manufacture's instruction (Sigma).2.7. Gene expression and mtDNA analysis
RNA from skeletal muscle tissue and C2C12 cells were extracted
with RNeasy mini kit (QIAGEN) according to the instructions and
quantiﬁed using a NanoDrop 1000 spectrophotometer (Thermo Sci-
entiﬁc). cDNA was synthesized with an iSCRIPT cDNA synthesis kit
(BioRad) using 200 ng of RNA. Quantitative RT-PCR reactions were
performed using 1 μM of primers and LightCycler® 480 SYBR Green
Master (Roche) on a LightCycler® 480 detection system (Roche). Cal-
culations were performed by a comparative method (2−ΔΔCT) using
actin as an internal control. For mtDNA analysis, total DNA was
extracted with a DNeasy blood and tissue kit (QIAGEN). mtDNA was
ampliﬁed using primers speciﬁc for the mitochondrial cytochrome c
oxidase subunit 2 (COX2) gene and normalized to genomic DNA by
ampliﬁcation of the ribosomal protein s18 (rps18) nuclear gene.
Primers were designed using the IDT software (IDT) and the primer
sequences can be found in the Supplemental Information.
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Citrate synthase activity was measured in both skeletal muscle tis-
sue and C2C12 cell lysates spectrophotometrically at 412 nm at 30 °C,
as previous described [42].Tissue or cell protein extracts (20 μg) were
added to buffer containing 10 mM Tris pH 8, 200 μM Acetyl CoA and
500 μM 5,5-dithio-bis-(2-nitrobenzoic) acid. The reaction was initiat-
ed by the addition of 1 mM oxaloacetate.
2.9. Mitochondrial mass
Mitochondrial mass was evaluated using the ﬂuorescent probe N-
nonyl acridine orange (NAO). Brieﬂy, C2C12 cells were incubated in
DMEM containing 10 nM of NAO for 30 min at 37 °C in the dark.
The cells were then trypsinized and resuspended in DMEM without
NAO. The NAO ﬂuorescence intensity was determined by ﬂow cyto-
metry on the FACSCalibur (BD Biosciences) using the 488 nm laser.
2.10. Immunoblot
Protein extracts from tissue or C2C12 cells were obtained by lysis in
ice-cold lysis buffer (150 mM NaCl, 10 mM Tris HCl (pH 7.4), 1 mM
EDTA, 1 mM EGTA, 1% Triton X-100, 0.5% NP-40) supplemented with a
cocktail of protease and phosphatase inhibitors (Roche). Protein content
was determined by the bicinchoninic acid protein assay (Pierce), and
50 μg of protein was run on SDS-PAGE under reducing conditions. The
separated proteins transferred to a polyvinylidene diﬂuoride membrane0 
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Fig. 1. Berberine protects from obesity and obesity-induced impairment in glucose homeost
Diet (HFD) and High Fat Diet supplemented with BBR (HFD+BRR) (n=5 experiments **pb
skeletal muscle of rats fed with Chow diet (Ctl), High Fat Diet (HFD) and High Fat Diet supp
body characteristics of rats fed with Chow diet (Ctl), High Fat Diet (HFD) and High Fat Diet su
versus HFD, §§ pb0.01 versus HFD, ++ pb0.01 versus Ctl, & pb0.05 versus HFD, pb0.05 v
glucose challenge were measured (D) and values for areas under the insulin curve were cal
plemented with BBR (HFD+BRR) (n=5 experiments **pb0.01 versus Ctl, # pb0.05 versus
High Fat Diet (HFD) and High Fat Diet supplemented with BBR (HFD+BRR). (n=4 experi
HFD). All data represent mean±SEM.(Perkin-Elmer). Proteins of interest were revealed with speciﬁc anti-
bodies: anti-phospho-AMPKα (Thr 172), anti- AMPKα, anti-phospho-
ACC (Ser79) (Cell Signaling Technology), anti-SIRT1 (Sigma-Aldrich),
anti-PGC1alpha (H300) (Santa Cruz Biotechnology), anti-NRF-1
(Abcam), anti-TFAM (Aviva Biosciences), anti-COXI, anti-COXIV (Mitos-
ciences) and anti-β-Actin (Sigma-Aldrich) overnight at 4 °C. The immu-
nostaining was detected using horseradish peroxidase-conjugated anti-
rabbit or anti-mouse immunoglobulin for 1 h at room temperature.
After the visualization of phospho-ACC or phospho-AMPKα, membranes
were stripped with Stripping buffer (100 mM Mercaptoethanol, 2% SDS
and 62.5 mM Tris–HCl buffer at pH 6.7) at 50 °C for 15 min and further
probed for the visualization of total ACC or AMPKα. Bands were revealed
using Amersham ECL detection system (GE Healthcare) and quantitated
by densitometry using Image J.2.11. NAD+/NADH measurement
NAD+/NADH ratio from C2C12 cells was quantiﬁed with a com-
mercially available kit (BioVision) according to the manufacturer's
instructions.2.12. Statistical analysis
Data were analyzed by a two-tailed unpaired Student's t-test. All
data are reported as mean±SEM. Statistical analysis was performed
using Excel software.### 
** 
Ctl HFD HFD 
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BBR 
ight (g) Fat-Free
mass (g)
Fat mass
(g)
Fat mass 
(%)
Fasting
glucose 
(mmol/l)
Fasting
insulin
(ng/ml)
0 ± 23 461 ± 35 98 ± 23 18 ± 4 5 ± 1 0.7 ± 0.3
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Group Leptin(nmol/l)
Adiponectin
(nmol/l)
Ctl 4433 ± 714 10406 ± 2958
HFD 20398 ± 4386*** 19713 ± 3079
HFD + 
BBR 579 ± 78
### 31943 ± 3290
asis in Sprague–Dawley Rats. (A) Body Weight of rats fed with Chow diet (Ctl), High Fat
0.01 versus Ctl, ## pb0.01 versus HFD). (B) Triglycerides content expressed in mg/dL in
lemented with BBR (HFD+BRR) (n=4 experiments p≥0.05). (C) Comparative whole
pplemented with BBR (HFD+BRR) (n=5 experiments **pb0.01 versus Ctl, ## pb0.01
ersus HFD). (D and E) Plasma glucose concentrations at the indicated time points after
culated (E) in rats fed with Chow diet (Ctl), High Fat Diet (HFD) and High Fat Diet sup-
HFD). (F) Leptin and Adiponectin content in the plasma of rats fed with Chow diet (Ctl),
ments **pb0.01 ***pb0.001 versus Ctl, ### pb0.001 versus HFD &&& pb0.001 versus
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3.1. BBR reverts high fat diet-induced obesity
Previous work has demonstrated that BBR protects from High fat
diet (HFD)-induced obesity and its deleterious effects. Also, BBR has
been shown to prevent the natural onset of obesity in several animal
models [25,26,28,30]. In our present work, we decided to investigate
the metabolic effects of BBR on skeletal muscle in a model of diet-
induced obesity.We administered BBR (100mg/kg/day) in the drinking
water for 4 weeks to rats previously fed with a HFD for 12 weeks. Body
weight measurements at the end of the experimental treatment vali-
dated the HFD feeding as amodel for obesity, since theHFD rats showed
a signiﬁcant increase in bodyweightwhen compared to control rats (on
average 160 gmore) (Fig. 1A). Moreover, we observed that both fat and
lean masses were contributing to this increase (Fig. 1C). This was also
correlatedwith an increase in the triglyceride content in skeletalmuscle
of HFD fed rats (Fig. 1B). BBR signiﬁcantly reduced this increase in body
weight to values similar to control rats (Fig. 1A) due to reversion of the
HFD inducing increase in both fat and lean mass induced by HFD feed-
ing (Fig. 1C), since weight loss is not purely from adipose mass loss
but also includes lean mass loss. BBR treatment also decreased the tri-
glyceride content in the skeletal muscle of these rats (Fig. 1B).G
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Fig. 2. Berberine Protects from obesity-induced skeletal muscle mitochondrial dysfunction in
skeletal muscle mitochondria from rats fed with Chow diet (Ctl), High Fat Diet (HFD) and
expressed in nAtomsO/min/mg protein (n=5 experiments **pb0.01 versus Ctl, # pb0.05 v
genase (B) and Cytochrome c Oxidase (C) activity in skeletal muscle of rats fed with Chow
measured polarographically and expressed in nAtomsO/min/mg protein (n=4 experiments
tometrically in skeletal muscle of rats fed with Chow diet (Ctl), High Fat Diet (HFD) and H
(n=4 experiments *pb0.05 versus Ctl, # pb0.05 versus HFD). (E) ATP content in isolate
(HFD) and High Fat Diet supplemented with BBR (HFD+BRR) (n=5 experiments p≥0.05)
1 fast mRNA measured by means of quantitative RT-PCR in skeletal muscle of rats fed with C
BRR) (n=4 experiments p≥0.05). (G) MyHCIIa and MyHCIIb mRNA analyzed by means o
(HFD) and High Fat Diet supplemented with BBR (HFD+BRR) (n=4 experiments ** pb0.01
tometrically in skeletal muscle of rats fed with Chow diet (Ctl), High Fat Diet (HFD) and Hig
periments *pb0.05 versus Ctl, # pb0.05 versus HFD). All data represent mean±SEM.3.2. BBR normalizes hormonal levels and glucose homeostasis
Hyperglycemia and hyperinsulinemia are common symptoms asso-
ciated with development of the Metabolic Syndrome [4]. BBR supple-
mentation reduced HFD-induced fasted plasma insulin levels (Fig. 1C),
indicating that BBR is able to decrease HFD-induced hyperinsulinemia.
However, despite abolishing the HFD-induced hyperinsulinemia BBR
supplementation did not effectively change fasting plasma glucose
levels (Fig. 1C). To further study the effects of BBR in glucose homeosta-
sis and insulin sensitivity, an oral glucose tolerance test was performed.
Concomitant with an increase in body weight, HFD feeding decreased
the ability to clear blood glucose, as demonstrated by glucose excur-
sions (Fig. 1D) and AUC (Fig. 1E). Despite theweak effect on fasting glu-
cose plasma levels, BBR supplementation was able to signiﬁcantly
improve glucose tolerance and hyperinsulinemia over HFD fed rats to
values comparable to the control group (Fig. 1C–E). Together this data
revel that BBR supplementation has a positive impact on glucose and in-
sulin homeostasis upon HFD feeding.
Leptin and adiponectin levels were also assessed since alterations in
the levels of these two adipokines have been extensively correlated
with obesity and obesity-related disorders [4]. Indeed, adiponectin
and leptin are the two main adipokines thought to contribute to sys-
temic abnormalities in both lipid and glucose homeostasis [43]. HFD0 
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High Fat Diet supplemented with BBR (HFD+BRR) measured polarographically and
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diet (Ctl), High Fat Diet (HFD) and High Fat Diet supplemented with BBR (HFD+BRR)
*pb0.05 versus Ctl, ## pb0.01 versus HFD). (D) ATPase activity measured spectropho-
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d mitochondria from skeletal muscle of rats fed with Chow diet (Ctl), High Fat Diet
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189A.P. Gomes et al. / Biochimica et Biophysica Acta 1822 (2012) 185–195fed rats presented a marked increase in leptin levels (Fig. 1F), which
was reverted by BBR supplementation (Fig. 1F). Moreover, BBR supple-
mentation also induces a dramatic increase in the plasmatic levels of
adiponectin (Fig. 1F), resulting in mitigation of the dramatic increase
in the leptin/adiponectin ratio induced by HFD.
3.3. Mitochondrial function is rescued by BBR
Mitochondria play an important role in the development of insulin
resistance and hyperglycemia [8,44]. Boosting mitochondrial activity
provides, at least in part, a potential mechanism by which several ther-
apeutic agents act [19–21]. In order to address whether the beneﬁcial
effects of BBR are related to its ability to alter mitochondrial function,
we evaluated the function of isolated mitochondria. As reported before,
HFD feeding induced mitochondrial dysfunction in skeletal muscle
(Fig. 2A–E). This was demonstrated by decreased oxygen consumption
(State 3), and decreased maximal oxygen consumption in the presence
of FCCP (vFCCP), which is dependent only on the oxidative efﬁciency of
the electron transport chain (Fig. 2A). These defects in mitochondrial0
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Fig. 3. SIRT1 is involved in the rescue of mitochondrial dysfunction induced by hyperglycemia
tential measuredwith TMRM ﬂuorescent probe and normalized tomg of protein in cells after 9
5 μM BBR, 10 μMDCHC and 5 μM BBR plus 1 μM EX- 527. Data was analyzed as percentage of u
versus 25 mM or FFAs, § pb0.05 versus 25 mM+BBR or FFAs+BBR,+ pb0.05 versus 25 mMo
96 h of treatment with hyperglycemia (25 mM) (C) or fatty acids (FFAs) (D) and exposed to 5 μ
mgprotein. (n=4 experiments *pb0.05 **pb0.01 versus Ctl, # pb0.05 versus 25 mMor FFAs, §
(E and F) Citrate Synthase activity measured spectrophotometrically in cells after 96 h of treatm
10 μM DCHC and 5 μM BBR plus 1 μM EX- 527. Data is expressed in nAtomsO/min/mg protein
pb0.01 § pb0.05 versus 25 mM+BBR or FFAs+BBR, + pb0.05 versus 25 mM or FFAs). All darespirationwere rescued by treatmentwith BBR. In accordancewith de-
creased mitochondrial function, mitochondrial ATP content was also
decreased by HFD feeding and this was rescued by BBR (Fig. 2E). The
changes in mitochondrial function induced by HFD feeding, seem to
be the result of impairments in the mitochondrial ATPase (Fig. 2D)
and electron transport chain (ETC) complexes like Succinate dehydro-
genase (SDH) (Fig. 2B) and Cytochrome c Oxidase (COX) (Fig. 2C).
BBR supplementation was able to revert mitochondrial dysfunction in-
duced by HFD by restoring ATPase and ETC activities (Fig. 2B–D). Al-
though BBR has previously been shown to negatively impact hepatic
mitochondrial function in in vitro assays or in cells exposed to concen-
trations higher than the one used in our study [27,30,45,46], we also ob-
served an improvement in the function of hepatic mitochondria
isolated from animals treated with BBR (data not shown). This suggests
a dose-dependent, indirect but positive action of BBR on mitochondria.
HFD-induced mitochondrial dysfunction was also correlated with
decreased oxidative type 1 ﬁbers (Fig. 2F) and a switch towards the gly-
colytic type II ﬁbers (Fig. 2G) while BBR supplementation increased ox-
idative ﬁber type in skeletal muscle (Fig. 2F and G) and slightly##
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190 A.P. Gomes et al. / Biochimica et Biophysica Acta 1822 (2012) 185–195decreased glycolytic type IIb ﬁbers (Fig. 2G). Citrate synthase activity in
HFD fed rats was also decreased, and this effect was again rescued by
BBR supplementation (Fig. 2H). These observations led us to speculate
that BBR supplementation may be rescuing mitochondrial function
from HFD damage by increasing mitochondrial biogenesis.3.4. BBR rescues mitochondrial function in a SIRT1-dependent manner
The observations from the in vivo studies were extended to cell cul-
ture models by investigating potential mechanisms for BBR's beneﬁcial
effects on mitochondrial function under conditions of excess of nutri-
ents. SIRT1has been highlighted as a potential therapeutic target for nu-
merous mitochondrial pathologies [19–21]. Its beneﬁcial effects are
associated with an induction of genes involved in oxidative phosphory-
lation and mitochondrial biogenesis, thereby increasing mitochondrial
ability to oxidize substrates. Since BBR has been shown to activate
AMPK, an upstream regulator of SIRT1 and mitochondrial biogenesis
[31], we tested if SIRT1 is involved in the protective mechanisms of
BBR in mitochondrial function. Initially, C2C12myotubes were exposed
to high glucose and high fatty acids (FFAs) for 96 h. These exposures in-
ducedmitochondrial dysfunction, as demonstrated by a decrease inmi-
tochondrial membrane potential and COX activity (Fig. 3A–D).
Interestingly, supplementation with BBR for 96 h prevented this loss
of mitochondrial function (Fig. 3A–D). Since it has been recently
shown that 10 μM BBR induces an increase in mitochondrial-derived
superoxide that leads to AMPK activation in endothelial cells [45], we
evaluated ROS generation in cells treated with BBR 5 μM for 96 h. No0 
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BBR supplementation (Data not shown).
Similar to BBR, DCHC, a SIRT1 activator (Fig. 3A–D), also prevented
the loss of mitochondrial function caused by high glucose or FFAs.
Moreover, incubation of C2C12 cells with both BBR and EX-527 (a
known inhibitor of SIRT1), completely blocked BBR-mediated preven-
tion of mitochondrial dysfunction induced by both high glucose and
FFAs (Fig. 3A–D). This indicates that the beneﬁcial effects of BBR on mi-
tochondrial function are at least partlymediated through SIRT1. To con-
ﬁrm this, C2C12 SIRT1 knockdown cells were generated (Fig. 4A).
Importantly, these cells were unable to differentiate into myotubes,
and consequently they were used in the myoblast form. Mitochondrial
membrane potential and ATP content were decreased in both control
and SIRT1 knockdown cells exposed to high glucose (Fig. 4B and C).
Again, BBR protected against mitochondrial dysfunction in the control
cells. However, in the SIRT1 knockdown cells BBRwas unable to protect
from hyperglycemia-induced mitochondrial damage (Fig. 4B and C).
3.5. Mitochondrial biogenesis is increased by BBR in a SIRT1-dependent-
manner
Hyperglycemia has been reported to induce mitochondrial dysfunc-
tion by decreasing mitochondrial biogenesis [8,47]. Moreover, recent
studies report that lipid overload in skeletal muscle may promote mito-
chondrial dysfunction by supplying an excessive amount of reducing
equivalents to the ETC-complexes, resulting in their inhibition [35,48].
Therefore, increasing mitochondrial biogenesis may constitute an impor-
tant approach in preventing FFA-inducedmitochondrial dysfunction. The0
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191A.P. Gomes et al. / Biochimica et Biophysica Acta 1822 (2012) 185–195increase in citrate synthase activity in the in vivo study suggested that
BBR treatment increased mitochondrial biogenesis (Fig. 2H). Further-
more, citrate synthase activity in C2C12 myotubes was decreased by
both hyperglycemia and FFAs while both BBR and DCHC prevented this
decrease (Fig. 3E and F). Interestingly, the beneﬁcial effects of BBR were
again blocked by treatment with EX-527 (Fig. 3E and F). To address if
BBR indeed increases mitochondrial biogenesis in a SIRT1-dependent
manner, we examined several parameters of mitochondrial biogenesis
in SIRT1 knockdown and control cells. BBR prevented the decrease inmi-
tochondrial DNA content (Fig. 4D) and mitochondrial mass (Fig. 4E) in-
duced by hyperglycemia in control cells. However, BBR did not affect
mitochondrial DNA content (Fig. 4D) nor mitochondrial mass (Fig. 4E)
in SIRT1 knockdown cells. In control cells, BBR prevented
hyperglycemia-induced decrease in the expression of several genes that
regulate mitochondrial biogenesis, such as PGC-1alpha, NRF-1, NRF-2
and TFAM (Fig. 5A), as well as nuclear-encoded (NDUFS8 and COX5b)
and mitochondrial-encoded mitochondrial genes (ND1 and COX1)
(Fig. 5B). However, in the SIRT1 knockdown cells, BBR did not show any
effect on the aforementioned genes. These results were also conﬁrmed
at the protein level (Fig. 5C). To assess the effects of BBR onmitochondrial
biogenesis in vivo, the expression and protein level of mitochondrial bio-
genesis regulators such as PGC-1alpha and TFAM and mitochondrial
genes COX1, COX2, and COX IV were analyzed. HFD feeding decreased0 
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and High Fat Diet supplemented with BBR (HFD+BRR). (n=4 experiments *pb0.05 **pb0the expression of these genes, and in all cases, this was rescued by BBR
treatment (Fig. 5D and E).
3.6. BBR increases the NAD+/NADH ratio
After observing that the effects of BBR on mitochondrial function
and biogenesis were dependent on SIRT1, we sought to elucidate
the mechanism by which BBR activates SIRT1. BBR did not directly ac-
tivate SIRT1 as evaluated with an in vitro activity assay (data not
shown), indicating that it likely does not function in the samemanner
as the commonly used Sirtuin Activating Compounds (STACs) [49].
Given that SIRT1 is known to be regulated by NAD+ and the NAD+/
NADH ratio, we measured their abundance in cells treated with BBR.
Interestingly, BBR prevented the decrease in the NAD+/NADH ratio
caused by hyperglycemia (Fig. 6A) in C2C12 myotubes. To explain
the increase in NAD+/NADH induced by BBR, we evaluated the
expression of nicotinamide phosphoribosyltransferase (NAMPT), the
rate-limiting factor in NAD+ biosynthesis. A decrease in NAMPT ex-
pression and consequent depletion of cellular NAD+ has been
shown as a mechanism linking high glucose and FFAs with SIRT1
downregulation [50]. Therefore, we tested whether BBR modulates
NAMPT expression in C2C12 cells. Gene expression of NAMPT
markedly increased after 6 h of BBR exposure (Fig. 6C), which wasF-2 TFAM TFB1M TFB2M 
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over, FK866, an inhibitor of NAMPT, blocked the induction of genes
that regulate mitochondrial biogenesis and also in nuclear-encoded
and mitochondrial-encoded mitochondrial genes by BBR (Fig. 6D).A B 
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BBR is known to activate AMPK [25,29] but the precise mechanism
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LKB1 [32]. Thus, we aimed to address in our models if BBR activates
AMPK, and if this activation is SIRT1-dependent. As described previ-
ously, BBR induces AMPK activation in vivo (Fig. 7A). In C2C12 control
cells, BBR rescued the decrease in AMPK phosphorylation (Thr172)
induced by hyperglycemia (Fig. 7B and C), as well as the decrease in
ACC phosphorylation (Ser79) (a direct target of AMPK activity)
(Fig. 7B). However, these effects were not observed in SIRT1 knock-
down cells (Fig. 7B and C). Moreover, genes involved in fatty acid ox-
idation (LCAD, MCAD, CPT1b) that are targets of AMPK, as well as
glucose uptake genes (GLUT1 and GLUT4), were also upregulated by
BBR in a SIRT1-dependent manner (Fig. 7D).
Since a dose and time-dependent mechanism for AMPK activation
by BBR, dependent on superoxide-generation has been shown [45],
we compared the effects of 5 and 20 μM BBR on C2C12 cells, at 6, 12
and 24 h. While at 5 μM, BBR increased mitochondrial membrane po-
tential, 20 μM BBR decreased this parameter at all time points
(Fig. 8A). This was associated with a decrease in ATP content elicited
by 20 μM BBR, that was not affected by SIRT1 knockdown (Fig. 8C).
This effect is consistent with published data showing inhibition of mi-
tochondrial oxygen consumption by this range of BBR concentrations.
Opposingly, 5 μM BBR increased NAD+/NADH ratio as early as 6 h in-
cubation (Fig. 8B), which led to an increase in ATP content only after
12 h of incubation with BBR (Fig. 8C). This data further supports a
dose-dependent, indirect but positive action of BBR on mitochondria
that is primarily mediated by SIRT1 activation.
4. Discussion
In the present study we have demonstrated that oral supplemen-
tation of BBR (100 mg/kg/day) rescues key features of the metabolic
syndrome, including insulin resistance and hyperleptinemia. This is
in agreement with several other studies that have demonstrated a
role for BBR in the protection against HFD-induced insulin resistance
and diabetes [25,30,46]. Notably, BBR not only acts in the insulin re-
sistant tissues, but has also been shown to protect pancreatic beta
cells function in high caloric and streptozotocin-induce diabetic0 
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probe (B) and NAD+/NADH ratio measured spectophotometricaly in C2C12 cells after 6 h
**pb0.01 versus DMSO, # pb0.05 ## pb0.01 ### pb0.001 versus DMSO). (C) ATP cont
shRNA (sh Ctl) after 6 h, 24 h, 48 h and 96 h of treatment with hyperglycemia (25 mM),
### pb0.001 versus 25 mM, § pb0.05 §§ pb0.01 versus 25 mM+BBR). All data representmodels [51–53]. Several studies have shown that BBR needs to be ad-
ministrated in high doses (380–560 mg/kg/day) in order to have a
beneﬁcial effect [25,27]. However, our data and a recent study [46]
show that BBR can protect from HFD feeding at a much lower dose
than previously described (100 mg/kg/day).
Here, we show for the ﬁrst time, that the beneﬁcial effects of BBR
are accompanied by an increase inmitochondrial function and biogen-
esis in skeletalmuscle. Our results also conﬁrm these ﬁndings in a cell-
based model. It is important to note that short term treatments with
BBR were previously reported to inhibit ETC complex I [27], decrease
ATP content in hepatocytes [29] and cause mitochondrial fragmenta-
tion, depolarization, and oxidative stress in K1735-M2 cells when
used at concentrations 2–5 times higher than the concentrations
used in this study [54]. Moreover, when BBR is incubatedwith isolated
liver mitochondria, mitochondrial respiration is inhibited and mito-
chondrial permeability transition is induced [55]. Therefore, while
our ﬁndings demonstrate improved mitochondrial function by BBR,
they do not rule out the possibility of toxic effects of BBR onmitochon-
dria under different conditions or at higher concentrations.
PGC-1alpha and some of its targets, such as NRF-1, NRF-2 and
TFAM, are known to be the main regulators of the mitochondrial bio-
genesis pathway [56] and ultimately regulate mitochondrial function
and ﬁber-type switch in skeletal muscle [57]. Our results show that
BBR rescues skeletal muscle from mitochondrial dysfunction caused
by HFD feeding, as well as from hyperglycemia and fatty acid expo-
sure. Our data strongly indicate that this effect is due to enhanced mi-
tochondrial biogenesis through the PGC-1alpha signaling pathway.
Furthermore, our results show that the beneﬁcial effects of BBR on
mitochondrial biogenesis and function are dependent on the pres-
ence of SIRT1, pointing to an essential role for SIRT1 in the molecular
pathway mediating the effects of BBR.
A recent study by Xia and colleagues showed that in hepatocytes,
short term treatment with BBR results in ATP depletion and that results
in AMPK activation [30]. Despite the apparent contradiction, we hy-
pothesize that short term treatments with higher doses of BBR induce
mitochondrial toxicity and ATP depletion, while a long term, lower
dose results in a SIRT1-dependent AMPK activation and increased96 
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sion of mitochondrial dysfunction induced by HFD, hyperglycemia and
fatty acid exposure. The ability of BBR to activate AMPK has been exten-
sively studied [25,29,58]. Nevertheless, the exact mechanism by which
this occurs remains elusive. It was previously reported that BBR inhibits
ETC complex I, thereby increasing the AMP/ATP ratio and thus activat-
ing AMPK [27]. Furthermore it was recently showed that
mitochondrial-derived superoxide and peroxynitrite are required for
BBR-induced AMPK activation in endothelial cells [47].
In this work, we demonstrate another mechanism by which BBR is
able to counteract the negative effects of excess nutrients on metabolic
homeostasis. In this case, AMPK activation is not a primary target but
probably a consequence of SIRT1 activation by BBR. This model explains
why BBR is able to improve mitochondrial and insulin sensitivity in an-
imals previously fed a high fat diet, and therefore exhibiting mitochon-
drial damage with impaired ATP formation, prior to BBR treatment.
Therefore, under the conditions of our study inhibition of ATP synthesis
by BBR probably is not the main trigger for AMPK activation and im-
provement of mitochondrial function. This is supported by assays with
C2C12 cells exposed to 5 or 20 μM BBR for 6, 12 or 24 h. Indeed, while
20 μM BBR decreases mitochondrial membrane potential and ATP con-
tent, 5 μM BBR has the opposite effect being dependent on the forma-
tion of NAD+ associated with increased NAMPT expression and SIRT1
activation. These observations provide evidence that SIRT1 plays a piv-
otal role in the cellular effects of BBR but does not rule out the involve-
ment of AMPK. Since SIRT1 regulates LKB1 through deacetylation [32], a
necessary step for AMPK activation, SIRT1 activation by BBRmay lead to
a secondary activation of AMPK. SIRT1 silencing blocks AMPK (Thr172)
and ACC (Ser67) phosphorylation. Our results show that gene silencing
of SIRT1 in skeletal muscle cells prevented BBR-induced AMPK activa-
tion as well as ACC (Ser67) phosphorylation. Further investigation will
be needed to sort out the interplay between LKB1, AMPK, and SIRT1 in
mediating the effects of BBR. However, recent work has shown that
the hypoglycemic action of BBR can be attributed to its acute activation
of the transport activity of GLUT1, an effect independent of AMPK acti-
vation [59]. Thus, the beneﬁcial effects of BBR on metabolic abnormali-
ties may involve mechanisms that are yet to be elucidated.
5. Conclusions
In summary, we provided new evidence that low concentrations of
BBR greatly improve mitochondrial function in both animal and cell-
based models of insulin resistance and diabetes. We report for the
ﬁrst time that these beneﬁcial effects involve the stimulation of mito-
chondrial biogenesis via a SIRT1-mediated mechanism, thereby pro-
tecting against the deleterious effects of HFD feeding, hyperglycemia
and fatty acids. We propose that BBR may be a natural therapeutic
agent useful in the treatment of type 2 diabetes, obesity and the meta-
bolic syndrome.
Conﬂict of interest declaration
D.A.S. is a consultant for Sirtris, a GSK company developing sirtuin-
based medicines. No other potential conﬂicts of interest were reported.
Acknowledgments
This work was supported by a grant from the Portuguese Founda-
tion for Science and Technology (PTDC/SAU-OSM/72443/2006).
A.P.G, F.V.D, J.S.T and A.T.V are recipients of individual fellowships
from the Portuguese Foundation for Science and Technology (SFRH/
BD/44674/2008, SFRH/BD/38372/2007, SFRH/BD/38467/2007 and
SFRH/BD/44796/2008 respectively). B.P.H. was supported by an
NSERC PGS-D fellowship. D.A.S is an Ellison Medical Foundation
senior scholar and is supported by The Paul F. Glenn Foundation for
medical research and a grant from NIH/NIA (ROI AG 028730).Appendix A. Supplementary data
Supplementary data to this article can be found online at doi:10.
1016/j.bbadis.2011.10.008.References
[1] P.G. Kopelman, Obesity as a medical problem, Nature 404 (2000) 635–643.
[2] D.W. Haslam, W.P. James, Obesity, Lancet 366 (2005) 1197–1209.
[3] B.D. Hegarty, S.M. Furler, J. Ye, G. Cooney, E.W. Kraegen, The role of intramuscular
lipid in insulin resistance, Acta Physiol. Scand. 178 (2003) 373–383.
[4] D.M. Muoio, C.B. Newgard, Obesity-related derangements in metabolic regula-
tion, Annu. Rev. Biochem. 75 (2006) 367–401.
[5] M. Krebs, M. Roden, Nutrient-induced resistance in human skeletal muscle, Curr.
Med. Chem. 11 (2004) 901–908.
[6] K.F. Petersen, S. Dufour, D.B. Savage, S. Bilz, G. Solomon, S. Yonemitsu, G.W. Cline,
D. Befroy, L. Zemany, B.B. Kahn, The role of skeletal muscle insulin resistance in
the pathogenesis of the metabolic syndrome, Proc. Natl. Acad. Sci. U. S. A. 104
(2007) 12587–12594.
[7] A.E. Civitarese, B. Ukropcova, S. Carling, M. Hulver, R.A. DeFronzo, L. Mandarino, E.
Ravussin, S.R. Smith, Role of adiponectin in human skeletal muscle biogenesis,
Cell Metab. 4 (2006) 75–87.
[8] A.P. Rolo, C.M. Palmeira, Diabetes and mitochondrial function: role of hyperglyce-
mia and oxidative stress, Toxicol. Appl. Pharmacol. 212 (2006) 167–178.
[9] D.E. Kelley, J. He, E.V. Menshikova, V.B. Ritov, Dysfunction of mitochondria in
human skeletal mucle in type 2 diabetes, Diabetes 51 (2002) 2944–2950.
[10] V.K. Mootha, C.M. Lindfren, K.F. Eriksson, A. Subramanian, S. Sihag, J. Lehar, P.
Puigserver, E. Carlsson, M. Ridderstrale, E. Laurila, N. Houstis, M.J. Daly, N. Patterson,
J.P. Mesirov, T.R. Golub, P. Tamaro, B. Spiegelman, E.S. Lander, J.N. Hirschhorn, D.
Altshuler, L.C. Groop, PGC-1alpha-responsive genes involved in oxidative phosphor-
ylation are coordinately downregulated in human diabetes, Nat. Genet. 34 (2003)
267–273.
[11] M.E. Patti, A.J. Butte, S. Crunkhorn, K. Cusi, R. Berria, S. Kashyap, Y. Miyazaki, I.
Kohane, M. Costello, R. Saccone, E.J. Landaker, A.B. Goldﬁne, E. Mun, R. DeFronzo,
J. Finlayson, C.R. Kahn, L.J. Mandarino, Coordinated reduction of genes of oxida-
tive metabolism in humans with insulin resistance and diabetes: potential role
of PGC1 and NRF1, Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 8466–8471.
[12] L.K. Heilbronn, S.K. Gan, N. Turner, L.V. Campbell, D.J. Chisholm, Markers of mito-
chondrial biogenesis and metabolism are lower in overweight and obese insulin-
resistant subjects, J. Clin. Endocrinol. Metab. 92 (2007) 1467–1473.
[13] C. Bonnard, A. Durand, S. Peyrol, E. Chanseaume, M.A. Chauvin, B. Morio, H. Vidal,
H.J. Rieusset, Mitochondrial dysfunction results from oxidative stress in skeletal
muscle of diet-induced insulin-resistant mice, J. Clin. Invest. 118 (2008) 789–800.
[14] T. Yokota, S. Kinugawa, K. Hirabayashi, S. Matsushima, N. Inoue, Y. Ohta, S. Hamaguchi,
M.A. Sobirin, T. Ono, T. Suga, S. Kuroda, S. Tanaka, F. Terasaki, K. Okita, H. Tsutsui, Oxi-
dative stress in skeletal muscle impairs mitochondrial respiration and limits exercise
capacity in type 2 diabetic mice, Am. J. Physiol. Heart Circ. Physiol. 297 (2009)
H1069–H1077.
[15] R.M. Reznick, G.I. Shulman, The role of AMP-activated protein kinase in mito-
chondrial biogenesis, J. Physiol. 574 (2006) 33–39.
[16] Z. Gerhart-Hines, J.T. Rodgers, O. Bare, C. Lerin, S.H. Kin, R. Mostoslavsky, F.W. Alt,
Z. Wu, P. Puigserver, Metabolic control of muscle mitochondrial function and
fatty acid oxidation through SIRT1/PGC-1alpha, EMBO J. 26 (2007) 1913–1923.
[17] M.C. Haigis, D.A. Sinclair, Mammalian sirtuins: biological inights and disease rel-
evance, Annu. Rev. Pathol. 5 (2010) 253–295.
[18] J.T. Rodgers, C. Lerin, W. Haas, S.P. Gygi, B.M. Speigelman, P. Puigserver, Nutrient
control of glucose homeostasis through a complex of PGC-1alpha and SIRT1, Na-
ture 434 (2005) 113–118.
[19] J.A. Baur, K.J. Pearson, N.L. Price, H.A. Jamieson, C. Lerin, A. Kalra, V.V. Prabhu, J.S.
Allard, G. Lopez-Lluch, K. Lewis, P.J. Pistell, S. Poosala, K.G. Becker, O. Boss, D.
Gwinn, M. Wang, S. Ramaswamy, K.W. Fishbein, R.G. Spencer, E.G. Lakatta, D. Le
Couteur, R.J. Shaw, P. Navas, P. Puigserver, D.K. Ingram, R. de Cabo, D.A. Sinclair,
Resveratrol improves health and survival of mice on a high-calorie diet, Nature
444 (2006) 337–342.
[20] M. Lagouge, C. Argmann, Z. Gerhart-Hines, H. Meziane, C. Lerin, F. Daussin, N.
Messadeq, J. Milne, P. Lambert, P. Elliot, B. Geny, M. Laakso, P. Puigserver, J.
Auwerx, Resveratrol improves mitochondrial function and protects against met-
abolic disease by activating SIRT1 and PGC-1alpha, Cell 127 (2006) 1109–1122.
[21] J.N. Feige, M. Lagouge, C. Canto, A. Strehle, S.M. Houten, J.C. Milne, P.D. Lambert, C.
Mataki, J. Auwerx, Speciﬁc SIRT1 activation mimics low energy levels and pro-
tects against diet-induced metabolic disorders by enhancing fat oxidation, Cell
Metab. 8 (2008) 347–358.
[22] H.W. Jeong, K.C. Hsu, J.W. Lee,M. Ham, J.Y. Huh, H.J. Shin,W.S. Kim, J.B.L. Kin, Berberine
suppresses proinﬂammatory responses throughAMPKactivation inmacrophages, Am.
J. Physiol. Endocrinol. Metab. 296 (2009) E955–E964.
[23] S. Bova, R. Padrini, W.F. Goldman, D.M. Berman, G. Cargnelli, On the mechanism of
vasodilating action of berberine: possible role of inositiol lipid signaling system, J.
Pharmacol. Exp. Ther. 261 (1992) 318–323.
[24] M.S. Choi, D.Y. Yuk, J.H. Oh, H.Y. Jung, S.B. Han, D.C. Moon, J.T. Hon, Berberine in-
hibits human neuroblastoma cell growth through induction of p53-dependent
apoptosis, Anticancer. Res. 28 (2008) 3777–3784.
[25] Y.S. Lee, W.S. Kim, K.H. Kim, M.J. Yoon, H.J. Cho, Y. Shen, J.M. Ye, C.H. Lee, W.K. Oh,
C.T. Kim, C. Hohnen-Behrens, A. Gosby, E.W. Kraegen, D.E. James, J.B. Kim, Berber-
ine, a natural plant product, activates AMP-activated protein kinase with
195A.P. Gomes et al. / Biochimica et Biophysica Acta 1822 (2012) 185–195beneﬁcial metabolic effects in diabetic and insulin-resistant states, Diabetes 55
(2006) 2256–2264.
[26] J.M. Brusq, N. Ancellin, P. Grondin, R. Guillard, S.Martin, Y. Saintillan,M. Issandou, In-
hibition of lipid synthesis through activation of AMP kinase: and additional mecha-
nism for the hypolipidemic effects of berberine, J. Lipid Res. 47 (2006) 1281–1288.
[27] N. Turner, J.Y. Li, A. Gosby, S.W. To, Z. Cheng, H. Miyoshi, M.M. Taketo, G.J. Cooney,
E.W. Kraegen, D.E. James, L.H. Hu, J. Li, J.M. Ye, Berberine and its more biologically
available derivative, dihydroberberine, inhibit mitochondrial respiratory complex
I: a mechanism for the action of berberine to activate AMP-activated protein ki-
nase and improve insulin action, Diabetes 57 (2008) 1414–1418.
[28] W.S. Kim, Y.S. Lee, S.H. Cha, H.W. Jeong, S.S. Choe, M.R. Lee, G.T. Oh, H.S. Park, K.U.
Lee, M.D. Lane, J.B. Kim, Berberine improves lipid dysregulation in obesity by con-
trolling central and peripheral AMPK activity, Am. J. Physiol. Endocrinol. Metab.
296 (2009) E812–E819.
[29] Z. Cheng, T. Pang, M. Gu, A.H. Gao, C.M. Xie, J.A. Li, F.J. Nan, J. Li, Berberine-stimulated
glucose uptake in L6 myotubes involves both AMPK and p38 MAPK, Biochim. Bio-
phys. Acta 1760 (2006) 1682–1689.
[30] X. Xia, J. Yan, J. Shen, K. Tang, J. Yin, Y. Zhang, D. Yang, H. Liang, J. Ye, J. Weng, Ber-
berine improves glucose metabolism in diabetic rats by inhibition of hepatic glu-
coneogenesis, PLoS One 6 (2011) e16556.
[31] C. Cantó, Z. Gerhart-Hines, J.N. Feige, M. Lagouge, L. Noriega, P.J. Elliott, P. Puigserver,
J. Auwerx, AMPK regulates energy expenditure by modulating NAD+ metabolism
and SIRT1 activity, Nature 458 (2009) 1056–1060.
[32] F. Lan, J.M. Cacicedo, N. Riderman, Y. Ido, SIRT1 modulation of the acetylation
satus, cytosolic localization, and activity of LKB1. Possible role in AMP-activated
protein kinase activation, J. Biol. Chem. 283 (2008) 27628–27635.
[33] L. Rossetti, D. Massillon, N. Barzilai, P. Vuguin, W. Chen, M. Hawkins, J. Wu, J.
Wang, Short term effects of leptin on hepatic gluconeogenesis and in vivo insulin
action, J. Biol. Chem. 272 (1997) 27758–27763.
[34] J.G. Jones, A. Fagulha, C. Barosa, M. Bastos, L. Barros, C. Baptista, M.M. Caldeira, M.
Carvalheiro, Noninvasive analysis of hepatic glycogen kinetics before and after
breakfast with deuterated water and acetaminophen, Diabetes 55 (2006)
2294–2300.
[35] T.R. Koves, J.R. Ussher, R.C. Noland, D. Slentz, M. Mosedale, O. Ilkayeva, J. Bain, R.
Stevens, J.R.B. Dyck, C.B. Newgard, G.D. Lopaschuk, D.M. Muoio, Mitochondrial
overload and incomplete fatty acid oxidation contribute to skeletal muscle insulin
resistance, Cell Metab. 7 (2008) 45–56.
[36] C. Frezza, S. Cipolat, L. Scorrano, Organelle isolation: functional mitochondria
from mouse liver, muscle and culture ﬁbroblasts, Nat. Protoc. 2 (2007) 287–295.
[37] A.P. Rolo, P.J. Oliveira, A.J. Moreno, C.M. Palmeira, Bile acids effect liver mitochon-
drial bioenergetics: possible relevance for cholestasis therapy, Toxicol. Sci. 57
(2000) 177–185.
[38] D.L. Brautigan, S. Ferguson-Miller, E. Margoliash, Mitochondrial cytochrome c:
preparation and activity of native and chemically modiﬁed cytochromes c,
Methods Enzymol. 53 (1978) 128–133.
[39] T.P. Singer, Determination of the activity of succinate, NADH, choline and glycer-
ophosphate dehydrogenases, Biochim. Biophys. Acta 1363 (1994) 100–124.
[40] A.T. Varela, A.P. Gomes, A.M. Simões, J.S. Teodoro, F.V. Duarte, A.P. Rolo, C.M. Palmeira,
Indirubin-3′-oxime impairsmitochondrial oxidative phosphorylation and preventsmi-
tochondrial permeability transition induction, Toxicol. Appl. Pharmacol. 233 (2008)
179–185.
[41] A.P. Rolo, C.M. Palmeira, K.B. Wallace, Mitochondrially mediated synergistic cell
killing by bile acids, Biochim. Biophys. Acta 1637 (2003) 127–132.
[42] P.A. Srere, H. Brazil, L. Gonen, The citrate condensing enzyme of pigeon breast
muscle and moth ﬂight muscle, Acta Chem. Scand. 17 (1963) S129–S134.[43] N.B. Ruderman, A.K. Saha, E.W. Kraegen, Minireview: malonyl CoA, AMP-
activated protein kinase, and adiposity, Endocrinology 144 (2003) 166–171.
[44] B.B. Lowell, G.I. Shulman, Mitochondrial dysfunction and type 2 diabetes, Science
307 (2000) 384–387.
[45] Y. Han, Q. Wang, P. Song, Y. Zhu, M.H. Zou, Redox regulation of AMP-activated
protein kinase, PLoS One 5 (2010) (2010) e15420.
[46] C. Chen, Y. Zhang, C. Huang, Berberine inhibits PTP1B activity and mimics insulin
action, Biochem. Biophys. Res. Commun. 397 (2010) 543–547.
[47] C.M. Palmeira, A.P. Rolo, J. Berthiaume, J.A. Bjork, K.B. Wallace, Hyperglycemia de-
creases mitochondrial function: the regulatory role of mitochondrial biogenesis,
Toxicol. Appl. Pharmacol. 225 (2007) 214–220.
[48] D.M. Muoio, T.R. Koves, Skeletal muscle adaptation to fatty acid depends on coor-
dinated actions of the PPARs and PGC1 alpha: implications for metabolic disease,
Appl. Physiol. Nutr. Metab. 32 (2007) 874–883.
[49] J.C. Milne, P.D. Lambert, S. Schenk, D.P. Carney, J.J. Smith, D.J. Gagne, L. Jin, O. Boss,
R.B. Perni, C.B. Vu, J.E. Bemis, R. Xie, J.S. Dish, P.Y. Ng, J.J. Nunes, A.V. Lynch, H.
Yang, H. Galonek, K. Israelian, W. Choy, A. Ifﬂand, O. Medvedik, D.A. Sinclair,
J.M. Olefsky, M.R. Jirousek, P.J. Elliott, C.H. Westphal, Small molecule activators
of SIRT1 as therapeutics for the treatment of type 2 diabetes, Nature 450 (2007)
712–716.
[50] S.V. de Kreutzenberg, G. Ceolotto, I. Papparella, A. Bortoluzzi, A. Semplicini, C.
Dalla Man, C. Cobelli, G.P. Fadini, A. Avogaro, Downregulation of the longevity-
associated protein sirtuin 1 in insulin resistance and metabolic syndrome: poten-
tial biochemical mechanisms, Diabetes 59 (2011) 1006–1015.
[51] Z.Q. Wang, F.E. Lu, S.H. Leng, X.S. Fang, G. Chen, Z.S. Wang, L.P. Dong, Z.Q. Yan, Fa-
cilitating effects of berberine on rat pancreatic islets through modulating hepatic
nuclear factor 4 alpha expression and glucokinase activity, World J. Gastroenterol.
14 (2008) 6004–6011.
[52] S.S. Lu, Y.L. Yu, H.J. Zhu, X.D. Liu, L. Liu, Y.W. Liu, P. Wang, L. Xie, G.J. Wang, Berber-
ine promotes glucagon-like peptide-1 (7–36) amide secretion in streptozotocin-
induced diabetic rats, J. Endocrinol. 200 (2009) 159–165.
[53] J. Zhou, S. Zhou, J. Tang, K. Zhang, L. Guang, Y. Haung, Y. Xu, Y. Ying, L. Zhang, D. Li,
Protective effect of berberine on beta cells in streptozotocin-and high carbohy-
drate/high-fat diet-induced diabetic rats, Euro. J. Pharmacol. 606 (2009)
262–268.
[54] G.C. Pereira, A.F. Branco, J.A. Matos, S.L. Pereira, D. Parke, E.L. Perkins, T.L. Seraﬁm,
V.A. Sardão, M.S. Santos, A.J. Moreno, J. Holy, P.J. Oliveira, Mitochondrially targeted
effects of berberine [Natural Yellow 18, 5,6-dihydro-9,10-dimethoxybenzo(g)-1,3-
benzodioxolo(5,6-a) quinolizinium] on K1735-M2mouse melanoma cells: compar-
ison with direct effects on isolated mitochondrial fractions, J. Pharmacol. Exp. Ther.
323 (2007) 636–649.
[55] C.V. Pereira, N.G. Machado, P.J. Oliveira, Mechanisms of berberine (natural yello
18)-induced mitochondrial dysfunction: interaction with the adenine nucleotide
translocator, Toxicol. Sci. 105 (2008) 408–417.
[56] R.C. Scarpulla, Transcriptional paradigms in mammalian mitochondrial biogene-
sis and function, Physiol. Rev. 88 (2008) 611–638.
[57] K.A. Rasbach, R.K. Gupta, J.L. Ruas, J. Wu, E. Naseri, J.L. Estall, B.M. Spiegelman,
PGC-1alpha regulates HIF2alpha-dependent switch in skeletal muscle ﬁber
type, Proc. Natl. Acad. Sci. U. S. A. 107 (2010) 21866–21871.
[58] D.Y. Lu, C.H. Tang, Y.H. Chen, I.H. Wei, Berberine suppresses neuroinﬂammatory
responses through AMPK-activated protein kinase activation in BV-2 microglia,
J. Cell. Biochem. 110 (2010) 697–705.
[59] A. Cok, C. Plaisier, M.J. Salie, D.S. Oram, J. Chenge, L.L. Louters, Berberine acutely
activates the glucose transport activity of GLUT1, Biochimie 93 (2011)
1187–1192.
